Supply of NIV Drugs for Directorate of Procurement (Navy) Islamabad

The Directorate of Procurement (Navy), Islamabad, invites sealed bids for the supply of NIV Drugs as per Tender No. 2583043/R-2511/380159/A dated 24 Oct 25. This procurement is specifically for the Directorate of Procurement (Navy) located at Naval Residential Complex, Sector E-8, Islamabad. The tender covers the supply of various medical drugs including Miconazole Nitrate Oral 2% Tube, Sodium Picosulphate Drops, Almond Oil, Alendronate tablets, and Diltiazem tablets among others as detailed in the tender documents. The technical scope requires firms to submit detailed technical offers including brand names, manufacturer details, and compliance with the PVMS/NIV lists. The medicines must have a minimum shelf life of two years at delivery, proper packaging, and compliance with national and international standards including cold chain facilities where applicable. Inspection and quality assurance will be conducted by the Pakistan Navy Medical Stores Depot and PNS Hafeez. Delivery is scheduled from 1st July 2026 to 30 June 2027 on a supply order basis. Eligible bidders must be registered with the Federal Board of Revenue (FBR) and appear on the Active Taxpayers List (ATL). Firms should preferably be registered with DGDP or willing to register provisionally. Submission of valid licenses such as DRAP license, GMP certificates, ISO certifications, and NTN/GST certificates is mandatory. Earnest Money in the form of a Call Deposit Receipt (CDR) must accompany the bid as per specified rates. The tender follows a single stage two envelope bidding procedure with separate technical and commercial offers. The tender closing date is set for 19th May 2026 at 1030 hours, with bids to be submitted at Tender Box No. 206 at DP (Navy), Islamabad. Bidders are advised to carefully follow the instructions regarding documentation, packaging, and submission to avoid disqualification. A practical tip for bidders is to ensure that the technical offer is complete and strictly adheres to the format and requirements specified in the tender documents, as incomplete or conditional offers will be rejected outright. This tender represents a significant opportunity for pharmaceutical suppliers to engage with a prestigious government department under clear and transparent procurement rules. The earnest money, technical bid, and financial bid must be prepared meticulously to comply with the Directorate's requirements and PPRA regulations.